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Abstract
Background: Glucose abnormalities in cystic fibrosis (CF) are common, but there is limited evidence to guide their
dietary management. Progressive impaired glucose tolerance eventually leads to cystic fibrosis-related diabetes
(CFRD), the most prevalent complication of CF, which is associated with increased morbidity and mortality.
Optimising glycaemic control improves clinical status and reduces mortality; insulin therapy is the primary means of
controlling glycaemia in CFRD, but its role in managing pre-diabetes is less clear. CF dietary therapy requires a high
calorie diet due to increased energy expenditure and malabsorption, but this energy-dense diet is typically high in
fat and sugar, and high sugar intakes often result in hyperglycaemia in individuals who have impaired glucose
handling. Current guidelines for the dietary management of glucose abnormalities in CF are based on clinical
consensus rather than empirical evidence. A systematic review conducted in 2012 on the effects of low glycaemic
index dietary intervention in CF concluded that there is a dearth of evidence in this area. This review will update
the systematic review by Balzer et al. in 2012 and will broaden the scope of their review to include any type of
dietary intervention for managing glucose abnormalities in CF.
Methods: Quantitative studies of dietary interventions to manage glucose abnormalities in individuals aged over
5 years with CF and glucose abnormalities will be reviewed. No limits will be placed on language or study design.
The comparator will be standard CF dietary therapy (energy dense, high-fat diet) in addition to insulin therapy for
individuals with CFRD. Electronic databases will be searched for completed quantitative studies published in peer-
review journals that focus on dietary interventions for managing glucose abnormalities in CF. Searches will be
conducted from 2000 up to the present day to reflect the evolving improvements in CF management. No
restrictions will be placed on study design or language. Duration of the dietary intervention must be a minimum of
2 months and only interventions in out-patient or community settings will be included. Studies must report on
dietary intervention, glycaemic control, anthropometry and lung function. Evidence will be assessed for
heterogeneity and a narrative review or meta-analysis conducted as appropriate.
Discussion: This systematic review will elucidate current knowledge of the effects of dietary interventions for
managing glucose abnormalities in the vulnerable CF clinical population.
Systematic review registration: PROSPERO registration number: CRD42018085569 www.crd.york.ac.uk/prospero/
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Background
There is limited evidence to guide dietary therapy for glu-
cose abnormalities in cystic fibrosis (CF). CF is a chronic,
life-limiting, genetic condition, characterised by abnormally
thick and dehydrated secretions which lead to organ ob-
struction, primarily affecting the lungs and the reproductive
and digestive systems [1]. Abnormalities in glucose metab-
olism are common and a spectrum of progressive glucose
tolerance abnormalities occur as individuals grow older; in-
determinate glycaemia is followed by impaired glucose tol-
erance (IGT), which affects 20% of 10-year-olds and 82% of
the CF population by the age of 30 years [2], before
CF-related diabetes (CFRD) eventually develops [3]. CFRD
is the most prevalent complication of CF [4], and it is a dis-
tinct form of diabetes which occurs in association with pan-
creatic insufficiency, primarily caused by pancreatic
damage. Its pathophysiology is complex and includes the
loss of pancreatic islet cells, leading to both insulin and glu-
cagon deficiency, and fluctuating insulin resistance caused
by chronic and acute inflammation and infection [4]. CFRD
is typically diagnosed in late adolescence or early adulthood
[5–7] and affects approximately 20% of adolescents and up
to 50% of adults with CF aged over 40 years [4, 5, 8]. The
early stages of CFRD is characterised by normal fasting glu-
cose but over time fasting hyperglycaemia develops [8]. The
combination of diabetes and CF leads to increased morbid-
ity and is associated with a sixfold increase in mortality [7,
9–11]. Fewer than a quarter of people with CFRD survive
beyond the age of 30 years, compared with 60% of CF indi-
viduals without diabetes [12, 13].
Optimising glycaemic control is known to improve
clinical status and pulmonary function and reduce mor-
tality [5]. Insulin therapy is the primary means of con-
trolling glycaemia in CFRD but its role in -pre-diabetes
is less clear [14]. The development of diabetes represents
the onset of a second chronic disease, adding further
complexity to daily CF treatment regimes. Individuals
are required to monitor and control their blood glucose
concentrations through regular blood glucose testing
and daily insulin injections. Treating IGT in CF with in-
sulin is controversial as it increases patient burden but it
is not yet known whether early initiation of insulin re-
duces morbidity and mortality in the longer term [15].
In cystic fibrosis, a high energy intake is required due to
increased energy expenditure and malabsorption, malnutri-
tion risk, and gut abnormalities including delayed gastric
emptying, altered intestinal motility and liver disease [7].
To date, there are no meta-analyses or randomised con-
trolled trials of dietary intervention to manage glucose ab-
normalities in CF, and current guidelines are based on
clinical consensus rather than empirical evidence [4, 8].
The goal of CFRD dietary management is to achieve and
maintain good nutritional status and normalise blood glu-
cose levels. There are important differences between CFRD
and non-CF diabetes, which necessitate a unique approach
to diagnosis and management [2]. In practice, due to the
lack of specific evidence-based guidelines for managing glu-
cose abnormalities in CF, standard CF nutritional recom-
mendations are frequently applied [4, 8]. However, the
energy-dense CF diet is typically high in fat and sugar, and
high sugar intakes often results in poor glycaemic control
in CF patients with glucose abnormalities. As in any clinical
group, patients vary in their specific nutritional needs, and
as such, dietary management must be tailored to meet these
needs. As practice varies, a consistency of approach and nu-
tritional targeting is needed in this vulnerable group.
Low glycaemic index (GI) dietary intervention has dem-
onstrated benefits in non-CF forms of diabetes, including
improved insulin sensitivity, glycaemia and quality of life in
both type 1 and type 2 diabetes [16], and it is now recom-
mended as part of their dietary management [17–19]. A
systematic review conducted in 2012 to assess understand-
ing of the effect of low GI dietary interventions in young
people with CF concluded that there is a dearth of evidence
in this area [20]. A scoping search of the literature has re-
vealed that there has been little further research in this field
since the 2012 review was conducted. The aim of the
current review is to update the 2012 systematic review by
Balzer et al. [20], to assess current understanding of gly-
caemic index dietary intervention in CF and to broaden the
scope of their review to include any type of dietary interven-
tion for managing glucose abnormalities in CF. Studies of
dietary interventions aimed at improving glycaemic control
in individuals over 5 years of age with CF and either IGT or
CFRD, will be considered for inclusion. The comparator is
standard CF dietary therapy (energy dense, high-fat diet), in
addition to insulin therapy for individuals with CFRD.
Outcomes will include glycaemic control (primary) and
anthropometry and lung function (secondary).
Methods
This protocol follows the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses for Protocols (PRIS-
MA-P) 2015 reporting guideline [21] (see Additional file 1).
The review is registered on PROSPERO International pro-
spective register of systematic reviews (www.crd.york.ac.uk/
prospero/); registration number: CRD42018085569. If any
amendments to this protocol are required when conducting
the review, these will be clearly described in the review art-
icle when prepared for publication.
Eligibility criteria
All completed, quantitative studies published in peer-review
journals that focus on dietary interventions to manage glu-
cose abnormalities in humans with CF will be included.
Due to the evolving improvements in CF management, all
articles published from 2000 will be screened to reflect
recent care. No limits will be placed on language.
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Participants
Individuals aged over 5 years with CF and either IGT or
CFRD will be included. No restrictions will be placed
on upper age, gender, CF mutation or other demograph-
ics. Differences in a variety of study level characteristics
may result in heterogeneity in the results (e.g. paediatric
vs adult patients, good vs poor CF control, transplant-
ation vs no transplantation). Study level characteristics
(covariates) that might explain any heterogeneity will be
documented and reported.
Glucose abnormalities are defined as follows:
 Oral glucose tolerance test (OGTT):
IGT:
120-min plasma glucose 7.8–11.1 mmol/l
OR
Glycated haemoglobin (HbA1c) ≥ 39 mmol/mol or
≥ 5.7%1
CFRD:
fasting plasma glucose concentration ≥ 7.0 mmol/l
OR
120-min plasma glucose ≥ 11.1 mmol/l
OR
HbA1c ≥ 48 mmol/mol or ≥ 6.5% [22]
Continuous glucose monitoring (CGM) time above
7.8 mmol/l ≥ 4.5% [23]2
All studies in all CF patients will be included, but any
additional medication that may affect glycaemia will be
acknowledged and if of substantial effect, analysed
separately.
Interventions
Any dietary intervention for managing glucose abnor-
malities in CF, with or without the use of insulin ther-
apy. Examples include low GI diets and carbohydrate
counting. Only dietary interventions of a 2-month dur-
ation or more, specifically being used to manage gly-
caemia in CF, will be included.
Comparator
There is currently no evidence-based consensus for the
dietary management of glucose abnormalities in CF, and
thus, the comparators will be standard CF dietary ther-
apy (energy dense, high-fat, high-salt diet [4]) for indi-
viduals with IGT and standard CF dietary therapy plus
insulin therapy for individuals with CFRD.
Setting
Diabetes management is primarily an out-patient based
speciality and therefore this review will be limited to
out-patients and community settings. Any studies solely
involving in-patient care will be excluded.
Outcomes
Primary outcomes are:
 Glycaemic control (OGTT, HbA1c; exploratory
outcome: % of CGM time above 7.8 mmol/L)
Secondary outcomes are:
 Body weight (kg)
 Height (m)
 BMI (kg/m2)/ BMI-SDS (children & adolescents,)
 Lung function (FEV1, FVC)
 Mortality/adverse events
 Adherence and acceptability of dietary intervention
Study design
A preliminary scoping search of the literature has identi-
fied limited evidence in this area. Therefore, all study de-
sign types will be included in this review (e.g. RCTs,
prospective and retrospective cohort, cross-sectional,
case control, case series). Results will be presented ac-
cording to study design.
Information sources
Relevant studies will be identified through a comprehen-
sive search of the following main electronic databases:
AMED, Embase, MEDLINE via OVID, Web of Science
and CENTRAL via Cochrane library. To reflect the evolv-
ing improvements in CF management, articles from 2000
up to the present day will be screened, and the first 20
pages of Google Scholar. Reference lists of all included
full-text articles will be hand-searched for additional ori-
ginal publications. OpenGrey will also be searched for any
additional grey literature. Conference abstracts will be
used to help identify potential studies. Conference ab-
stracts from the following major CF and diabetes confer-
ences will be included: International Conference of Cystic
Fibrosis, North American Cystic Fibrosis Conference,
European Cystic Fibrosis Society, Cystic Fibrosis Founda-
tion Research Conference, American Diabetes Associ-
ation, European Association for the Study of Diabetes,
European Society of Paediatric Endocrinology, Inter-
national Diabetes Federation. Study authors will be con-
tacted to establish if full-text articles are available or to
request any missing data as required.
Search strategy
A draft literature search strategy for MEDLINE database
has been developed by the lead author (LB) and an expe-
rienced systematic reviewer (RP), using a combination of
Medical Subject Headings (MeSH) and keyword terms.
This search strategy is presented in Fig. 1. The search
strategy will be revised appropriately for each database
to take into account differences in controlled vocabulary
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Fig. 1 Draft search strategy including planned limits (MEDLINE database)
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and syntax rules. A preliminary scoping search of
Embase, MEDLINE via OVID and Web of Science data-
bases has been conducted. The search strategy presented
in Fig. 1 is a refined version of this preliminary search
strategy.
Data management
EndNote X8.2 reference management software package will
be used to manage all the search results throughout the re-
view period. Covidence screening and extraction tool may
also be utilised to help manage the review process.
Selection process
Titles and abstracts will be assessed for eligibility by two
members of the review team (LB, RP). Articles that ap-
pear to meet the inclusion criteria will be retrieved in
full and independently considered for inclusion by two
members of the review team (LB, JHS). The reviewers
will resolve disagreements in opinion of studies for in-
clusion through discussion, and the reasons for exclud-
ing studies will be recorded.
Data collection process
Data from full-text articles for inclusion will be extracted
independently by two reviewers (LB, RP) using a stan-
dardised data extraction template. The template will be
piloted by both reviewers before starting the review and
modified as required to ensure consistency. The follow-
ing data will be extracted from each study: study design;
sample characteristics (size, inclusion/exclusion criteria,
sex, age, socioeconomic status); dietary intervention; re-
sults (including but not limited to glycaemic control, an-
thropometric measures, lung function, adherence and
acceptability of dietary intervention); analysis methods;
study limitations; and funding sources. Disagreements in
opinion of data extracted will be resolved through
discussion.
Risk of bias/quality assessment
Full-text articles of all included research studies will be
assessed for methodological quality independently by two
members of the review team (LB, RP). The Cochrane Risk
of Bias tool [24] will be used for RCTS and ROBINS-I tool
[25] for observational studies. Any discrepancies between
the two reviewers will be resolved through discussion or
third-party adjudication. The quality of all included stud-
ies will be assessed using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
system [26].
Data synthesis
A narrative review of the findings from the included
studies will be presented, structured around the out-
comes reported. Meta-analysis will be performed only if
the identified studies are comparable. The primary out-
comes of this review will be continuous variables, and
we anticipate that mean values will be reported for all
continuous outcomes. Results reporting categorical out-
comes will be reported separately. Sub-group analysis
based on age (children, adults), glucose abnormality
(CFRD, IGT), CF control (good control vs poor control)
and transplantation (transplant vs no transplant) will be
conducted if there are sufficient numbers of comparable
studies. Results will be pooled for comparable sub-sets
of studies only where possible.
The preliminary scoping search conducted revealed a
relatively small number of studies which appeared to be
very diverse. Considerable heterogeneity between studies
is therefore anticipated. Where there are sufficient stud-
ies deemed comparable, in respect of both the dietary
intervention and the outcomes under consideration,
their individual effect sizes will be illustrated using forest
plots together with combined estimates, using random
effect models. Study level characteristics (covariates) that
might explain any heterogeneity, such as age, nutritional
status and CF control, will be documented and reported.
Sub-group analyses as outlined above will be undertaken
together with meta-regression if indicated.
Discussion
This systematic review will elucidate current knowledge
of the effects of dietary interventions for managing glu-
cose abnormalities in cystic fibrosis and will highlight
areas where further research is needed to inform dietary
recommendations for this vulnerable clinical population.
Endnotes
1The applicability of HbA1c in the CF population is
controversial due to increased red blood cell turnover
[3] but will be included in this review to be as inclusive
as possible.
2Exploratory outcome is not a validated definition of
diabetes
Additional file
Additional file 1: PRISMA-P 2015 Checklist. PRISMA-P checklist adapted
for use with systematic review protocol submissions to BioMed Central
journals. (DOCX 33 kb)
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